Loratadine is a second-generation antihistamine drug for the treatment of allergic diseases including allergic rhinitis and ...

Loratadine, a widely prescribed second-generation antihistamine, is commonly used to treat allergic conditions such as hay ...

Morepen Laboratories approved for Loratadine export to China, aiming to strengthen global position in anti-allergy API market.

Morepen Laboratories has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for its Loratadine (anti-allergy API). This marks a ...

Urticaria highlights from AAD 2025 include late-breaking results from a phase 1b/2a study of the anti-c-Kit antibody ...

Ascilion's products for dermal interstitial fluid sampling will be the focus of six different presentations at the Microneedles 2025 Conference.</ ...

Adults with chronic spontaneous urticaria experienced greater mortality, probably due to increased risks for comorbidities, ...

Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn's disease 1,2< ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)Strategic ...

Corporate Updates: In January 2025, Septerna appointed Gil Labrucherie, CFA, J.D., as chief financial officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior ...